港股公告掘金 | 石药集团：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准

智通财经

2024-12-30

重大事项：

开拓药业-B(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验 III 期阶段完成首例受试者入组

科济药业-B(02171)：舒瑞基奥仑赛注射液用于治疗晚期胃╱食管胃结合部腺癌的中国关键II期临床试验取得初步阳性结果

石四药集团(02005)：尼可刹米已获批准登记成为在上市制剂使用的原料药

康希诺生物(06185)：曼海欣®获得印度尼西亚注册证书

威胜控股(03393)附属公司中标南方电网招标项目

石药集团(01093)：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准

华检医疗(01931)拟投资人工智能液冷解决方案公司并申请美国场外交易市场跨境交易

贵州银行(06199)拟收购铜仁丰源80%的股份并将其改建为支行

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2495294265"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2495294265\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2495294265?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-12-30 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495294265","market":"hk","top_or_hot":-1,"title":"港股公告掘金 | 石药集团：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准","media":"智通财经","content":"<html><body><p><strong>重大事项：</strong></p><p><a href=\"https://laohu8.com/S/09939\">开拓药业-B</a>(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验 III 期阶段完成首例受试者入组</p><p><a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)：舒瑞基奥仑赛注射液用于治疗晚期胃╱食管胃结合部腺癌的中国关键II期临床试验取得初步阳性结果</p><p><a href=\"https://laohu8.com/S/02005\">石四药集团</a>(02005)：尼可刹米已获批准登记成为在上市制剂使用的原料药</p><p><a href=\"https://laohu8.com/S/06185\">康希诺生物</a>(06185)：曼海欣®获得印度尼西亚注册证书</p><p><a href=\"https://laohu8.com/S/03393\">威胜控股</a>(03393)附属公司中标南方电网招标项目</p><p><a href=\"https://laohu8.com/S/01093\">石药集团</a>(01093)：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准</p><p><a href=\"https://laohu8.com/S/01931\">华检医疗</a>(01931)拟投资人工智能液冷解决方案公司 并申请美国场外交易市场跨境交易</p><p><a href=\"https://laohu8.com/S/06199\">贵州银行</a>(06199)拟收购铜仁丰源80%的股份并将其改建为支行</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>港股公告掘金 | 石药集团：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 石药集团：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准\n</h2>\n<h4 class=\"meta\">\n\n\n2024-12-30 23:16 北京时间   <a href=\"http://www.zhitongcaijing.com/content/detail/1231344.html\"><strong>智通财经</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>重大事项：开拓药业-B(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验 III 期阶段完成首例受试者入组科济药业-B(02171)：舒瑞基奥仑赛注射液用于治疗晚期胃╱食管胃结合部腺癌的中国关键II期临床试验取得初步阳性结果石四药集团(02005)：尼可刹米已获批准登记成为在上市制剂使用的原料药康希诺生物(06185)：曼海欣®获得印度尼西亚注册证书威胜控股(...</p>\n<a href=\"http://www.zhitongcaijing.com/content/detail/1231344.html\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B031HY20.USD","symbol_name":"FSSA CHINA GROWTH \"I\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1231344.html","article_id":"2495294265","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495294265","pubTimestamp":1735571818,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"重大事项：开拓药业-B(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验 III 期阶段完成首例受试者入组科济药业-B(02171)：舒瑞基奥仑赛注射液用于治疗晚期胃╱食管胃结合部腺癌的中国关键II期临床试验取得初步阳性结果石四药集团(02005)：尼可刹米已获批准登记成为在上市制剂使用的原料药康希诺生物(06185)：曼海欣获得印度尼西亚注册证书威胜控股(0339","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","01093":"石药集团","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","HSCEI":"国企指数","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","HSTECH":"恒生科技指数","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","07226":"XL二南方恒科","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","YANG":"三倍做空富时中国ETF-Direxion","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1141":"生命科学工具和服务","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK1576":"医药外包概念","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","03347":"泰格医药","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","BK1515":"抗疫概念","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1583":"高瓴概念","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC"},"translate_title":"Hong Kong Stock Announcement Nuggets Stone Pharmaceutical Group: Leuprorelin Sustained-Release Injection (SYH 9016) Approved for Clinical Trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"YANG":1,"HSTECH":1,"HSCEI":1,"01093":1,"07226":1},"content_text":"重大事项：开拓药业-B(09939)：KX- 826 酊1.0%治疗中国成年男性雄激素脱发关键性临床试验 III 期阶段完成首例受试者入组科济药业-B(02171)：舒瑞基奥仑赛注射液用于治疗晚期胃╱食管胃结合部腺癌的中国关键II期临床试验取得初步阳性结果石四药集团(02005)：尼可刹米已获批准登记成为在上市制剂使用的原料药康希诺生物(06185)：曼海欣®获得印度尼西亚注册证书威胜控股(03393)附属公司中标南方电网招标项目石药集团(01093)：亮丙瑞林缓释注射液(SYH 9016)获临床试验批准华检医疗(01931)拟投资人工智能液冷解决方案公司 并申请美国场外交易市场跨境交易贵州银行(06199)拟收购铜仁丰源80%的股份并将其改建为支行","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}